http://www.wikio.co.uk/blog/search/Eli Lilly and Company Wikio Blogs - search: Eli Lilly and Company wikio wikio http://www.wikio.co.uk/info?id=68357421 ST. LOUIS, Aug. 20 /PRNewswire-FirstCall/ -- Monsanto Company (NYSE: MON) announced today that it has entered into an agreement to sell its POSILAC(R) bovine somatotropin brand and related business to Eli Lilly and Company (NYSE: ). Lilly's animal health division, Elanco, headquartered in Greenfield, Indiana, is the seventh largest animal health company on a global sales basis. Under the terms of the agreement, Lilly will purchase assets and liabilities of Monsanto associated with the POSILAC brand and related business for an upfront payment of $300 million, plus additional contingent consideration. The transaction will be completed as soon as practical. Additional terms of the agreement were not disclosed. Elanco has been marketing recombinant bovine somatotropin for Monsanto over the last decade outside the United States under a licensing agreement. "We're pleased Elanco is acquiring this business and will continue to provide dairy farmers with this important production tool," said Carl Casale, Monsanto's Executive Vice-President of Strategy and Operations. "Elanco is fully focused on animal health and productivity and is committed to the importance of POSILAC in both the domestic and the international marketplace." POSILAC bovine somatotropin is an FDA-approved animal pharmaceutical used by U.S. dairy farmers to increase productivity. Since it was first sold in the United States in 1994, POSILAC has become the country's leading dairy animal supplement. POSILAC safely increases productivity of dairy cows thereby allowing family farm owners to more easily provide for their family and employees, reinvest in their farms, and conserve resources like land, water and energy. Over the past 14 years, more than a half billion units of POSILAC have been successfully and safely used by tens of thousands of dairy producers on millions of cows to produce wholesome, nutritious, safe and affordable milk and dairy products. About Monsanto Company Monsanto Company is a l Wed, 20 Aug 2008 13:00:00 GMT http://www.wikio.co.uk/info?id=68357421 2008-08-20T13:00:00Z http://www.wikio.co.uk/info?id=67713719 United Arab Emirates: EMC Corporation, the world leader in information infrastructure solutions, today announced that Eli Lilly and Company, a leading innovation-driven pharmaceutical corporation, has recognized EMC with their 2008 Global Sustained Supplier Award. [AMEInfo.com] Thu, 14 Aug 2008 07:43:40 GMT http://www.wikio.co.uk/info?id=67713719 AME Info | United Arab Emirates | Latest News 2008-08-14T07:43:40Z http://www.wikio.co.uk/info?id=67490932 Pharmaceutical Leader Recognizes EMC for Outstanding Service in IT Integration HOPKINTON, Mass., Aug. 12 /PRNewswire/ -- EMC Corporation (NYSE: ), the world leader in information infrastructure solutions, today announced that Eli Lilly and Company (NYSE: ), a leading innovation-driven pharmaceutical corporation, has recognized EMC with their 2008 Global Sustained Supplier Award. The Sustained Supplier Award recognizes suppliers who have a long-term relationship with Lilly, and have shown continuous improvement in supplier relationship management, quality, service, tier II supplier diversity, speed, and total cost reduction to Lilly while working with Lilly in a collaborative business model. Frank Hauck, EMC Executive Vice President, Global Marketing and Customer Quality, said, "EMC strives to provide the best total customer experience in the industry by continuing to deliver innovative technology and solutions, backed by the world's best service and support. The Global Sustained Supplier Award is a testament to EMC's value as a strategic IT partner to the pharmaceutical industry. We are deeply appreciative of Lilly's recognition of our efforts." For more than a decade, EMC has been helping the world's leading pharmaceutical companies reduce the complexity of IT environments and ensure continuous uptime for their most critical research, clinical trials, manufacturing, and business applications. By properly storing, managing, and securing critical information, pharmaceutical companies can streamline drug discovery processes as they develop medicines, enabling them to bring high-value therapeutics to market faster and enabling people to live healthier, more active lives. For more information on EMC's pharmaceutical solutions, visit: About EMC EMC Corporation (NYSE: ) is the world's leading developer and provider of information infrastructure technology and solutions that enable organizations of all sizes to transform the way they compete and create value Tue, 12 Aug 2008 13:00:00 GMT http://www.wikio.co.uk/info?id=67490932 2008-08-12T13:00:00Z http://www.wikio.co.uk/info?id=65375609 Eli Lilly and Company has teamed up with Vision Racing and Polymer Technology Systems, Inc. as a partner in the recently announced Vision Racing Wellness Tour to provide free diabetes educational information as well as cholesterol screenings at the IndyCar Series during the 2008 racing season. Thu, 24 Jul 2008 11:00:00 GMT http://www.wikio.co.uk/info?id=65375609 2008-07-24T11:00:00Z http://www.wikio.co.uk/info?id=65370106 Wellness Tour Mobile Unit Offers Free Diabetes Education and Cholesterol Screenings to Race Spectators INDIANAPOLIS, Ind., July 24 /PRNewswire-FirstCall/ -- Eli Lilly and Company has teamed up with Vision Racing and Polymer Technology Systems, Inc. as a partner in the recently announced Vision Racing Wellness Tour to provide free diabetes educational information as well as cholesterol screenings at the IndyCar Series during the 2008 racing season. Eli Lilly and Company, a worldwide leader in diabetes treatment, research and education, will provide the diabetes education component of the Wellness Tour Mobile Unit, including a free diabetes risk assessment and access to a certified diabetes educator. Team partner Polymer Technology Systems will provide its revolutionary CardioChek(R) home cholesterol test system to complete a cholesterol screening. The goal of the Vision Racing Wellness Tour is to leverage the popularity of the IndyCar Series to promote overall health management by providing tools and ongoing community-based support for those living with, treating or at-risk for serious health conditions, such as diabetes, high cholesterol and heart disease to help improve the health and wellness of communities across the country. "The number of people with diabetes in the U.S. is increasing at an alarming rate, and, through this initiative, Lilly can play a role in helping manage its impact on individuals and our communities," said Rob Brown, vice president and chief marketing officer, Lilly USA. "Together with Vision Racing, we're helping to provide education about diabetes, along with practical, everyday solutions to help people affected by diabetes live healthier lives." "So many people are living with high cholesterol but aren't aware of it," said Robert Huffstodt, president and CEO of Polymer Technology Systems, Inc. "Because of this, we are excited to join the Vision Racing Wellness Tour to help provide people with cholesterol screenings so that they Thu, 24 Jul 2008 13:00:00 GMT http://www.wikio.co.uk/info?id=65370106 2008-07-24T13:00:00Z http://www.wikio.co.uk/info?id=68389615 INDIANAPOLIS, Ind., Aug. 20 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: ) today announced that it has completed the acquisition of SGX Pharmaceuticals, Inc. (Nasdaq: ), a San Diego-based biotechnology company focused on drug discovery and development in the area of oncology. The completion of the deal followed today's Special Stockholders Meeting, in which a majority of SGX stockholders voted in favor of the merger agreement with Lilly. Under the agreement, Lilly will today acquire all of the outstanding shares of SGX common stock at a price of $3.00 per share. All other closing conditions have also been met. (Logo: ) The deal, valued at a total purchase price of $64 million, will allow Lilly to integrate SGX's structure-guided drug discovery platform into its drug discovery efforts. It will also give Lilly access to FAST(TM), SGX's fragment-based, protein structure guided drug discovery technology, and to a portfolio of pre-clinical oncology compounds focused on a number of high-value kinase targets. "We are pleased to complete the acquisition of SGX and are excited to bring the scientific and technological expertise of SGX into Lilly's research organization," remarked Steven M. Paul, M.D., executive vice president, science and technology for Lilly. "We will leverage the combined resources of both companies to strengthen our structural biology capabilities and seek out innovative therapies for patients." The impact of the acquisition, including a one-time charge to earnings for acquired in-process research and development, will be reflected in Lilly's third quarter 2008 financial results. About Eli Lilly and Company Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers Wed, 20 Aug 2008 17:23:00 GMT http://www.wikio.co.uk/info?id=68389615 2008-08-20T17:23:00Z http://www.wikio.co.uk/info?id=68357424 Deal Provides Strategic Fit with Lilly's Animal Health Division GREENFIELD, Ind., Aug. 20 /PRNewswire-FirstCall/ -- Elanco, a division of Eli Lilly and Company (NYSE: ), today announced that Lilly has signed an agreement to acquire the worldwide rights to the dairy cow supplement, Posilac(R) (sometribove), as well as the product's supporting operations, from Monsanto Company (NYSE: ). "Global dairy demand is increasing, outstripping supply, and consumers are seeing rapidly rising prices," said Jeff Simmons, president, Elanco. "With the purchase of Posilac, Elanco can enhance its overall product portfolio and work together with the industry to provide dairy farmers more options and give consumers affordable choices. Critically, we remain focused on the health and care of the cow in working with farmers to increase global milk supply. "With our rich history and experience in the dairy industry, Elanco is the ideal steward of this vital technology," Simmons said. "Elanco remains committed to using science to address the growing need for safe, affordable food; and to choices for consumers, retailers and producers." Elanco has exclusively sold sometribove outside of the United States for a decade. Posilac has been safely used for more than 14 years. Under the terms of the agreement, Lilly will acquire all rights to the Posilac brand, as well as the product's U.S. sales force and its manufacturing facility in Augusta, Georgia. In return, Monsanto will receive a $300 million upfront payment, as well as contingent consideration. The Posilac dairy business manufacturing and sales teams will be integrated into the Elanco business. The transaction is expected to close near the beginning of the fourth quarter of 2008, contingent upon clearance under the Hart-Scott-Rodino Anti-Trust Improvements Act and other customary closing conditions. Lilly confirmed that the acquisition will not result in a change to the company's full-year 2008 financial guidance, as detailed in Wed, 20 Aug 2008 13:00:00 GMT http://www.wikio.co.uk/info?id=68357424 2008-08-20T13:00:00Z http://www.wikio.co.uk/info?id=68116081 We are faced with a large problem, one requiring resources and creativity, the very things that a free market is supposed to unleash. The problem is drug-resistant bacteria and diseases that cannot be cured with existing strains of antibiotics. Yet market incentives are perverse. The marketplace is just as often our enemy as our friend. [...] Mon, 18 Aug 2008 14:52:40 GMT http://www.wikio.co.uk/info?id=68116081 Mark Tokarski 2008-08-18T14:52:40Z http://www.wikio.co.uk/info?id=66896347 Covance Inc., a leading provider of drug development services, announced August 6 that it signed a definitive agreement with Eli Lilly and Company to help transform Lilly’s R&D model. Under the agreement, Covance will acquire Lilly’s 450-acre... Wed, 06 Aug 2008 20:19:16 GMT http://www.wikio.co.uk/info?id=66896347 admin 2008-08-06T20:19:16Z http://www.wikio.co.uk/info?id=67716318 BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that the independent Drug Safety Monitoring Board (DSMB) for the MAESTRO-01 trial has conducted the scheduled interim analysis of efficacy and safety and has recommended that the trial continue to completion. MAESTRO-01 is the pivotal phase II/III Canadian and [...] Thu, 14 Aug 2008 09:12:58 GMT http://www.wikio.co.uk/info?id=67716318 admin 2008-08-14T09:12:58Z http://www.wikio.co.uk/info?id=67548582 Toronto Stock Exchange Symbol: MS EDMONTON, Aug. 12 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the second quarter ended June 30, 2008. BioMS Medical, in partnership with Eli Lilly and Company (Lilly), is developing MBP8298 (dirucotide), a drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the US. "The three randomized late-stage clinical trials for MBP8298 (dirucotide) continue to progress very well. We recently announced that MAESTRO-03, our U.S. phase III secondary progressive MS trial, was fully recruited with approximately 510 patients," said Kevin Giese, President and CEO of BioMS Medical. "During the quarter, BioMS was also honored to receive the Gold Leaf Award from BIOTECanada in recognition of our selection as "Company of the Year". Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for MBP8298 (dirucotide): (x) MAESTRO-01: A randomized, double-blind pivotal phase II/III trial in Canada and Europe evaluating MBP8298 (dirucotide) for the treatment of secondary progressive MS (SPMS). The study has completed full recruitment of 611 patients at 47 trial sites in 10 countries. Patients are administered either MBP8298 (dirucotide) or placebo every six months for a period of two years. To date, there have been eight positive safety reviews from the Data Safety Monitoring Board (DSMB). (x) MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal trial. Eligible patients who have successfully completed the blinded, placebo controlled MAESTRO-01 trial may choose to receive MBP8298 (dirucotide) on an un-blinded basis. To date, approximately 95% of patients enrolled in MAESTRO-01 have proceeded to MAESTRO-02. (x) MAESTRO-03: A U.S. pivotal phase III trial evaluating MBP8298 (dirucotide) for the treatment of SPMS. Enrollment for the randomized, double-blin Tue, 12 Aug 2008 22:32:00 GMT http://www.wikio.co.uk/info?id=67548582 2008-08-12T22:32:00Z http://www.wikio.co.uk/info?id=66842974 Lilly to Lease New Elanco Global Headquarters in Hancock County, Indiana R&D restructuring aimed at increasing productivity and reducing drug development costs; U.S. clinical trial monitoring work and data management also to be transferred INDIANAPOLIS, Aug. 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: ) today announced that Covance Inc. (NYSE: ), one of the world's leading drug development services companies, will buy and operate Lilly's Greenfield Laboratories located in Greenfield, Indiana. In addition, Lilly is finalizing plans to lease a new worldwide headquarters for its animal health division, Elanco, in Hancock County, Indiana. The announcement is part of a series of actions the company is taking to restructure its research and development organization in order to compete in a dramatically changing environment. These moves will help improve productivity by gaining speed to market and lowering drug development costs, while supporting the continued growth of Elanco. "For nearly a century, Greenfield Laboratories has been an important Lilly site, currently housing Elanco's worldwide headquarters and a significant portion of Lilly's toxicology testing, as well as other R&D support functions," said John Lechleiter, Ph.D., Lilly's president and chief executive officer. "These actions reflect Lilly's determination to take the necessary steps to compete in a very challenging marketplace, in which our customers are demanding innovative, high-quality, affordable medicines. These are difficult but necessary decisions we must make in order to compete successfully as an independent Indiana-based company," Lechleiter added. Covance to buy Lilly's Greenfield Laboratories Lilly will sell its Greenfield Laboratories site and transfer operations to Covance for an up-front payment of $50 million. The two companies also will sign a 10-year service agreement. Under this agreement, Lilly and Covance will broaden their existing strategic collaboration, w Wed, 06 Aug 2008 13:00:00 GMT http://www.wikio.co.uk/info?id=66842974 2008-08-06T13:00:00Z http://www.wikio.co.uk/info?id=66377617 CARLSBAD, Calif., Aug. 1 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: ), a specialized laboratory services provider, announced the election of Karin Eastham and Laurence R. McCarthy, Ph.D. to its Board of Directors, effective as of July 30, 2008. Ms. Eastham has been elected to serve as a Class I director of Genoptix until the 2011 Annual Meeting of Stockholders and will also serve on the Audit Committee of the Board of Directors. Dr. McCarthy has been elected to serve as a Class II director of Genoptix until the 2009 Annual Meeting of Stockholders and will also serve on the Compliance Committee of the Board of Directors. "We look forward to the contributions of Ms. Eastham and Dr. McCarthy as members of the Genoptix Board of Directors. Each bring their individual expertise in their fields and personal style of leadership, adding diversity of opinion and further strengthening the leadership of the company as we move forward," said Dr. Tina Nova Bennett, president and CEO of Genoptix. Karin Eastham has served as the Executive Vice President, Chief Operating Officer, and Trustee for the Burnham Institute for Medical Research since 2004. Prior to this, Ms. Eastham was the Senior Vice President of Finance and the Chief Financial Officer for Diversa Corporation. She has also served in similar senior level management roles at Combichem, Inc., Cytel Corporation and Boehringer Mannheim Diagnostics. She currently serves on the Boards of Directors for multiple life science companies including Illumina, Inc., and Amylin Pharmaceuticals, Inc. She also serves on the boards of Tercica, Inc. and SGX Pharmaceuticals, Inc., which have entered into definitive merger agreements pursuant to which such companies will be acquired by Ipsen, S.A. and Eli Lilly and Company, respectively, subject to various conditions including stockholder approval. Ms. Eastham earned her MBA in Finance and B.S. in Accounting from Indiana University and is a member of the American Institute of Certi Fri, 01 Aug 2008 21:19:00 GMT http://www.wikio.co.uk/info?id=66377617 2008-08-01T21:19:00Z http://www.wikio.co.uk/info?id=65991806 Living with ADD/ADHD Dear Healthline Member! New ADHD Drug Approved by the FDA On May 8, 2008, Eli Lilly and Company was granted marketing approval by the U.S. Food and Drug Administration (FDA) for its drug Strattera® (atomoxetine HCl), which is to be used for maintenance of ADHD in children and adolescents. First approved in 2002 for ADHD in adults, Strattera®—a selective norepinephrine reuptake inhibitor—is the first nonstimulant the FDA has approved to treat ADHD in children, adolescents and adults. Find out more about ADHD and its respective treatments. Find out more » Kids Advised to Have Heart Health Checked Before Starting ADHD Meds Children with attention deficit hyperactivity disorder (ADHD) who take stimulant drugs for their condition are advised to get cardiac evaluation and monitoring—such as an electrocardiogram (ECG)—before treatment. Stimulant medications can increase heart rate and blood pressure, which can be a bad problem for a child with ADHD who also has a diagnosed or undiagnosed heart condition. Get the latest information on ADHD medication risks in our special report from Harvard Health Publications. Read more » ADHD Affects Sleeping Patterns in Kids Sleep problems are common in children with ADHD. Up to 73 percent of kids with ADHD suffer from trouble falling asleep, resisting going to bed and being overly tired when waking up in the morning. In turn, this may translate to the child being late for school and the parent being late for work. Watch our video that discusses how to help kids with ADHD succeed in school. Watch now» Are ADHD Kids Even Being Diagnosed? Do you think your child has ADHD? If so, has he or she been diagnosed? Furthermore, are they being treated? The fact of the matter is that among children who meet the diagnostic criteria of ADHD, only half are being diagnosed—and an even smaller portion are being treated Find out more about this problem in our special report from Harvard Health Publications. Read more » Remove yourself from future email here Healthline 660 3rd St San Francisco, CA 94107 United States This message was sent to banderozzz.antib@blogger.com pmguid:b1.80lf.37ys Tue, 29 Jul 2008 22:29:00 GMT http://www.wikio.co.uk/info?id=65991806 anton 2008-07-29T22:29:00Z http://www.wikio.co.uk/info?id=66164900 Eli Lilly and Company (NYSE: LLY) announced interim results of its Phase II study of LY2062430, an investigational anti-amyloid beta monoclonal antibody for the treatment of mild to moderate Alzheimer’s disease. In this study, intravenously administered LY2062430 bound to the amyloid beta protein, resulting in increased amounts of amyloid beta in participants’ blood and cerebrospinal [...] Thu, 31 Jul 2008 10:05:23 GMT http://www.wikio.co.uk/info?id=66164900 admin 2008-07-31T10:05:23Z